Bencycloquidium Bromide Nasal Spray
ApprovedSmall molecule
Bencycloquidium Bromide Nasal Spray is one of 30 small molecule programs targeting Allergic Rhinitis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
271 competitors in Allergic Rhinitis
#DrugCompanyPhaseTrials
1Kenalog
BBassett Healthcare
Phase 3
Comparator: Statins
Merck & Co.Phase 3
Bepreve
BBausch Health Americas, Inc.
Phase 3
Standard Adjuvant ET
Eli LillyPhase 3
Flonase
TevaPhase 3
Bencycloquidium Bromide Nasal Spray
YYingu Pharmaceutical Co., Ltd
Approved
Ciclesonide HFA
Sumitomo Pharma America, Inc.Phase 3
Asmanex
NovartisPreclinical
Administration of Comparator
EEurofarma Laboratorios S.A.
Phase 3
Veramyst
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- YYingu Pharmaceutical Co., Ltd